Form 4: ARS Pharma CBO Sells All Direct Shares

ARS Pharmaceuticals' Chief Business Officer, Justin Chakma, sold all his directly held common stock after exercising options, totaling 166,380 shares.

Summary

• Justin Chakma, Chief Business Officer of ARS Pharmaceuticals, Inc. (SPRY), reported transactions on November 12, 2025.
• Exercised options to acquire 30,000 shares of common stock at an exercise price of $0.84 per share.
• Sold 30,000 shares of common stock at a weighted average price of $8.9119, with prices ranging from $8.87 to $8.97.
• Sold an additional 136,380 shares of common stock at a weighted average price of $8.8634, with prices ranging from $8.62 to $9.04.
• Following these transactions, Chakma's direct beneficial ownership of common stock is 0 shares.
• Chakma still beneficially owns 89,047 stock options.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 4

Explanation: While the sales were pre-planned under a 10b5-1 plan, the complete divestment of direct common stock by a C-level executive is generally viewed with caution by investors, indicating a potentially less positive outlook from an insider perspective, despite the profitable nature of the transaction for the individual.

Positives

• The exercise of options at a low price ($0.84) and subsequent sale at significantly higher prices (around $8.90) indicates a profitable transaction for the insider.
• The transactions were conducted under a Rule 10b5-1(c) plan, suggesting pre-planned sales rather than opportunistic timing based on non-public information.

Negatives

• The Chief Business Officer sold all directly held common stock, which could be interpreted by the market as a lack of confidence in the company's near-term prospects by a key executive.
• Significant insider selling can sometimes put downward pressure on the stock price due to market perception.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the complete sale of direct holdings by a key executive as a negative signal regarding the company's future prospects, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

While the complete divestment of direct shares by a C-level executive is a notable event, the transaction was executed under a Rule 10b5-1 plan, which suggests a pre-scheduled sale rather than an immediate reaction to new information. Investors should monitor future insider activity and company performance, but a 'hold' recommendation is appropriate given the pre-planned nature of the sale, avoiding an immediate 'sell' unless further negative catalysts emerge.

Keywords

ARS Pharmaceuticals, SPRY, Justin Chakma, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Chief Business Officer, Rule 10b5-1